Perspective from Medical Community | Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD

International Hepatitis Cure & Eradication Meeting 2015

Perspective from health economics | David Rein, PhD

International Hepatitis Cure & Eradication Meeting 2015

Session 4 Roundtable discussion

International Hepatitis Cure & Eradication Meeting 2015

Rational pricing and the role of generics | Raymond Schinazi, PhD, DSc

International Hepatitis Cure & Eradication Meeting 2015

Hepatitis C treatment | Manal El-Sayed, MD, PhD

International Hepatitis Cure & Eradication Meeting 2015

Perspective from Payers | Mel Krajden, MD, FRCPC

International Hepatitis Cure & Eradication Meeting 2015

Perspective from Payers | Bonnie Henry, MD, MPH, FRCPC

International Hepatitis Cure & Eradication Meeting 2015

Maximizing SVR with current HCV therapy | Alnoor Ramji, MD, FRCP

International Hepatitis Cure & Eradication Meeting 2015

New Treatment in HCV: Is there need for more therapies? | Jordan Feld, MD, MPH

International Hepatitis Cure & Eradication Meeting 2015

New Treatment Strategies for Hepatitis B | Harry Janssen, MD, PhD

International Hepatitis Cure & Eradication Meeting 2015

New tools for testing and monitoring Hepatitis B and C | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

International Hepatitis Cure & Eradication Meeting 2015

Baby Boomer Screening in the U.S: Delivering on the promise thus far? | John Ward, MD

International Hepatitis Cure & Eradication Meeting 2015

Point-of-care (POC) testing in Hepatitis B and C | Scott Bowden, PhD

International Hepatitis Cure & Eradication Meeting 2015

Session 1 Panel Discussion

International Hepatitis Cure & Eradication Meeting 2015

A hepatitis C Vaccine: How do we prove it works? | Kimberly Page

International Hepatitis Cure & Eradication Meeting 2015

Hepatitis C Vaccines: Are we making progress? | Christopher M. Walker, PhD

International Hepatitis Cure & Eradication Meeting 2015